Recent Updates
Recently added Catalysts
CTMX

CytomX Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference

Key Takeaway: SOUTH SAN FRANCISCO, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology plat

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate at Cowen and Company’s 40th Annual Health Care Conference in Boston, Massachusetts.
Date: Tuesday, March 3, 2020
Time: 10:00 a.m. E.T / 7:00 a.m. P.T.
Location: Boston, Massachusetts
A live audio of this webcast will be available through the “Investors & News” section of CytomX's website. An archived replay will be available for 60 days following the event.
About CytomX Therapeutics
Probody® is a registered trademark of CytomX Therapeutics Inc.
Investors and Media:
VP, Investor Relations and Corporate Communications
Last updated: Feb 25, 2020